Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Upgraded by Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by equities research analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research note issued to investors on Wednesday, MarketBeat reports. The firm presently has a $42.00 price objective on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 19.66% from the company’s previous close.

Separately, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 20th.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $35.10 on Wednesday. The firm has a market cap of $1.97 billion, a PE ratio of 31.62 and a beta of 0.70. The firm’s 50 day moving average price is $32.57 and its two-hundred day moving average price is $33.42. Supernus Pharmaceuticals has a twelve month low of $27.05 and a twelve month high of $40.28.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SUPN. MQS Management LLC bought a new stake in Supernus Pharmaceuticals in the second quarter worth approximately $279,000. AlphaQuest LLC grew its position in Supernus Pharmaceuticals by 360.0% in the second quarter. AlphaQuest LLC now owns 22,391 shares of the specialty pharmaceutical company’s stock worth $706,000 after acquiring an additional 17,523 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Supernus Pharmaceuticals in the second quarter worth approximately $1,536,000. Mutual of America Capital Management LLC grew its position in Supernus Pharmaceuticals by 5.3% in the second quarter. Mutual of America Capital Management LLC now owns 212,691 shares of the specialty pharmaceutical company’s stock worth $6,704,000 after acquiring an additional 10,726 shares in the last quarter. Finally, Yousif Capital Management LLC grew its position in Supernus Pharmaceuticals by 1.5% in the second quarter. Yousif Capital Management LLC now owns 21,032 shares of the specialty pharmaceutical company’s stock worth $663,000 after acquiring an additional 305 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.